Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 15, 2018− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –
NEWTON, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and...
-
Mar 8, 2018Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET
NEWTON, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year...
-
Mar 1, 2018
NEWTON, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Feb 7, 2018
NEWTON, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Feb 1, 2018
NEWTON, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Jan 31, 2018
NORWALK, Conn. and NEWTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation (MMRF), the world’s number one private funder of multiple myeloma research, and...
-
Jan 25, 2018− Biogen Brings Expertise in Development and Commercialization of Products for Neurological and Neurodegenerative Diseases –
NEWTON, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) today announced its entry into an agreement for Biogen to acquire Karyopharm’s investigational oral...
-
Jan 3, 2018
NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Dec 10, 2017− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex —
NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of four posters highlighting...
-
Dec 10, 2017− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma —
NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of Phase 1/2 clinical data...